Engineering a Monoclonal Antibody Therapy for Canine Mast Cell Tumors

SUMMARY: The fellow plans to develop a new, targeted therapy for mast cell tumors that employs a specially created monoclonal antibody designed to destroy mast cells.

THE PROBLEM: Mast cell tumors (MCT) are the most common skin tumors in dogs. MCTs can vary in their growth from slow growing to highly aggressive tumors, and treatment options are often limited, especially for tumors that have spread or can't be removed. Chemotherapy is sometimes used but has side effects. Despite treatment, most dogs eventually succumb to disease within a year of diagnosis. This highlights the need for more effective and precise therapy.

THE PROJECT: This study focuses on developing a new treatment using monoclonal antibodies (mAbs). mAbs are already used to treat many human cancers, but in veterinary medicine, they are still new and not widely available. The antibodies are designed to target the protein KIT on mast cells. KIT is present on mast cells but not on other immune cells. By targeting KIT, the antibodies can precisely attack cancer cells while leaving healthy cells unharmed.

Researchers will evaluate how well these mAbs bind to KIT and kill cancer cells. The mAbs will be engineered to work more effective for dogs by designing them to look like natural canine antibodies.

POTENTIAL IMPACT: By developing a safe and effective therapy for dog mast cell cancer, this research could be a game-changer in the treatment of MCT in dogs and could also serve as a model for treating similar conditions in other species that suffer from mast cell diseases, including humans and cats.